Chimeric Therapeutics Launches $6.6 Million Capital Raise to Fuel Clinical Trials

Highlights:

• $6.6 million raised through an oversubscribed two-tranche placement, backed by institutional and professional investors including a US-based family office.
• Funds to accelerate clinical trials of CHM CDH17 CAR-T and CORE-NK programs, targeting solid tumors and leukemia.
• Company terminates prior agreement with Lind Global Fund II, LP, signaling a new strategic funding direction.

Melbourne, Australia – May 20, 2025:

Clinical-stage biotech firm Chimeric Therapeutics Limited (ASX: CHM) has secured firm commitments to raise $6.6 million (before costs) through a two-tranche placement, the company announced today. At the time of writing, the raise received strong backing from institutional, sophisticated, and professional investors, including cornerstone support from a US-based family office.

Oversubscribed Placement to Fund Pipeline Expansion

The capital raise will be conducted in two tranches at an issue price of $0.004 per share—representing a 50% discount to Chimeric's last traded price and a 44% discount to its 15-day volume-weighted average price. The placement includes approximately 1.65 billion new fully paid shares and a corresponding number of options with the potential to unlock further capital via a piggyback mechanism. Each exercised option within five months will trigger an additional option exercisable at $0.005.

Tranche 1 comprises roughly 164.3 million shares ($657,000) and will be allotted under existing placement capacity, while Tranche 2—subject to shareholder approval—will issue around 1.49 billion shares ($5.943 million), with an extraordinary general meeting expected in July 2025.

Funding Key CAR-T and NK Therapy Trials

Proceeds will primarily support advancement of the CHM CDH17 CAR-T program, which has shown encouraging early results in gastrointestinal and neuroendocrine cancers. Funds will also go toward CORE-NK Phase 1B trials in acute myeloid leukemia and general working capital.

Following this capital raise, Chimeric has also chosen to terminate its prior placement agreement with Lind Global Fund II, LP, marking a strategic funding shift.

Chimeric CEO Dr. Rebecca McQualter said, “The overwhelming investor support reinforces confidence in our innovative cell therapy programs and enables us to accelerate key clinical milestones.”

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com